CGBIO, a South Korea-based company, earned the FDA’s investigational device exemption approval for its Novosis putty for spinal fusions.
The bone graft incorporates rhBMP-2 and is designed to enhance high-density bone formation and minimize ectopic bone growth, according to a news release. The rhBMP-2 protein in Novosis is manufactured by a strategic partner of CGBIO.
The FDA’s IDE approval opens up the opportunity to study the bone graft in spinal fusions in the U.S.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.